Darunavir:
Darunavir is an second-generation HIV-1 protease inhibitor. Researchers in China reported on February 4, 2020, that darunavir could inhibit SARS-CoV-2 infection in vitro. Experimental studies indicated that darunavir at a concentration of 300 μM significantly inhibits in vitro viral replication, and its efficiency was 280-fold in the treated group than that in the untreated group[7]. In trial number NCT04252274[41], darunavir is used in combination with cobicistat for patients with COVID-19 pneumonia. FDA approved this combination therapy for AIDS patients currently. Darunavir is an HIV-1 protease inhibitor, and cobicistat is an inhibitor of cytochrome P450 (CYP3A) that enhance pharmacokinetics and pharmacodynamics of darunavir[41]